These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15339751)

  • 21. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
    Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
    Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
    Crowell EB; Jubelirer SJ
    W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
    Kondo M; Hoshi SL; Toi M
    Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How do we interpret the results of the Breast Cancer Prevention trial?
    Margolese RG
    CMAJ; 1998 Jun; 158(12):1613-4. PubMed ID: 9645175
    [No Abstract]   [Full Text] [Related]  

  • 30. The benefits and costs of tamoxifen for breast cancer prevention.
    Eckermann SD; Martin AJ; Stockler MR; Simes RJ
    Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
    Lundkvist J; Ekman M; Ericsson SR; Isacsson U; Jönsson B; Glimelius B
    Radiother Oncol; 2005 May; 75(2):179-85. PubMed ID: 15885828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
    Smith TJ; Hillner BE
    J Clin Oncol; 2000 Jan; 18(2):284-6. PubMed ID: 10637241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population.
    Noah-Vanhoucke J; Green LE; Dinh TA; Alperin P; Smith RA
    Cancer; 2011 Aug; 117(15):3322-31. PubMed ID: 21404271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer prevention: a summary of the chemoprevention trial with tamoxifen.
    Gould K; Gates ML; Miaskowski C
    Oncol Nurs Forum; 1994 Jun; 21(5):835-40. PubMed ID: 7937245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventive health program aims to reduce cost, incidence of breast cancer.
    Clin Resour Manag; 2001 Feb; 2(2):26-9, 18. PubMed ID: 11246807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.